$ABT News

This Dividend King Just Announced Great News for Investors

Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment

Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test

Abbott Laboratories: A New Growth Story Takes Shape

Abbott Laboratories (ABT) Posted Higher Sensitivity Data For Colorectal Cancer Recurrence Detection

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery

Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122

Abbott (ABT) Stock Shrugs Off Q3 Results As Spin Off Looms

Abbott Laboratories' 2026 Guidance Cut Driven by Diabetes, Electrophysiology Portfolio, RBC Says

India regulator pulls up Nestlé, Abbott over infant-formula violations

Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook

RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125

Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119

Abbott to spin-off nutrition into standalone business

Abbott to spin-off nutrition into standalone business

JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118

TD Cowen Maintains Buy on Abbott Laboratories, Lowers Price Target to $118

Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123